Financial Data and Key Metrics Changes - Net sales for Q2 were $341 million, a 5% decline year-over-year, with a 2% favorable impact from foreign exchange [6][11] - The gross margin rate improved to 8.2%, a 160 basis point increase from 6.6% in the same period last year [11] - Adjusted operating income was $15.3 million, or 4.5% of net sales, compared to $13.3 million, or 3.7% of net sales last year [12] Business Line Data and Key Metrics Changes - Medical sales were $96 million, up 15% year-over-year, representing 28% of total company sales [6][10] - Automotive sales totaled $162 million, down 13% year-over-year, accounting for 48% of total sales [8][10] - Industrial sales were $83 million, a 5% decrease year-over-year, making up 24% of total sales [10] Market Data and Key Metrics Changes - Medical vertical growth was driven by increases in Poland and Thailand, while North America remained flat [6][7] - Automotive sales declined primarily in North America due to the transfer of an electronic braking program and tariff pressures [8][9] - Industrial business saw a decline in North America, offset by higher sales in Europe due to a rebound in the smart meter business [10] Company Strategy and Development Direction - The company is focusing on the medical vertical as a key growth area, leveraging its capabilities in a highly regulated industry [5][7] - A rebranding to Kimball Solutions reflects the company's evolution beyond traditional manufacturing services, expanding into design, engineering, and supply chain management [18] - The grand opening of a new medical manufacturing facility in Indianapolis is part of the strategy to enhance capabilities and capacity [5][7] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the medical vertical's growth potential, driven by megatrends such as an aging population and increasing healthcare access [7] - The company is monitoring the outlook for FY27, particularly in North American automotive and industrial sectors, due to economic concerns and tariff impacts [17] - Management raised guidance for fiscal 2026, expecting net sales to be in the range of $1.4-$1.46 billion, driven by strength in the medical vertical [15][16] Other Important Information - Cash and cash equivalents at the end of Q2 were $77.9 million, with positive cash flow for the eighth consecutive quarter [14] - The company invested $4.3 million in share repurchases during Q2, with a total of $109.5 million returned to shareholders since October 2015 [15] Q&A Session Summary Question: What percentage was Nexteer in December? - Nexteer accounted for 20% of sales in December [23][24] Question: What is the capacity and ramp expectations for the new facility in Indianapolis? - The new facility is 300,000 sq ft, significantly larger than the current footprint, with significant growth opportunities anticipated [26] Question: How should we think about growth in the automotive piece for Q3 and Q4? - Q3 automotive is expected to be flat to slightly up as the company anniversaries the end of the EB100 program [34] Question: What are the win rates and sizes of new programs? - Win rates remain consistent, with larger programs expected from lift and shift opportunities and CMO discussions [36][39] Question: How will the new facility impact margins? - In the near term, the new facility will drag margins due to depreciation and additional expenses, but long-term margins are expected to improve [42][43] Question: How do you see cash cycle days play out in the coming quarters? - Cash conversion days are expected to decrease in Q3 from elevated levels in Q2 [46]

Core Viewpoint - Analysts project that Edwards Lifesciences will report quarterly earnings of $0.62 per share, reflecting a year-over-year increase of 5.1%, with revenues expected to reach $1.54 billion, an 11.1% increase from the same quarter last year [1]. Earnings Projections - The consensus EPS estimate has been revised upward by 0.7% in the past 30 days, indicating a reassessment of initial estimates by covering analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Key Metrics Estimates - Analysts estimate 'Net Sales by Product Group - Transcatheter Mitral and Tricuspid Therapies' will reach $151.63 million, a 44.3% increase year-over-year [5]. - The consensus for 'Net Sales by Product Group - Surgical Structural Heart' is $259.76 million, suggesting a 6.3% year-over-year change [5]. - 'Net Sales by Product Group - Transcatheter Aortic Valve Replacement' is projected at $1.13 billion, reflecting an 8.9% increase from the previous year [6]. - 'Net Sales - Europe' is estimated at $385.24 million, indicating a 12.1% year-over-year change [6]. - 'Net Sales - Outside of the United States' is expected to be $656.66 million, a 14.6% increase year-over-year [7]. - 'Net Sales - United States' is projected at $881.08 million, reflecting an 8.4% increase from the year-ago quarter [7]. - 'Net Sales - Japan' is estimated to reach $92.30 million, indicating a 7.5% year-over-year change [7]. - 'Net Sales - Rest of World' is projected at $179.12 million, reflecting a 25% increase from the previous year [8]. Stock Performance - Edwards Lifesciences shares have decreased by 6% over the past month, contrasting with the Zacks S&P 500 composite's increase of 0.5%, and the company holds a Zacks Rank 3 (Hold), suggesting it will closely follow overall market performance in the near term [8].

Financial Data and Key Metrics Changes - Total as-reported revenue grew 9% in the third quarter, with constant currency organic revenue increasing by 8% driven by volume and a 200 basis points price increase [4] - Gross margin declined by 70 basis points to 43.9%, primarily due to increased tariffs and inflation [4] - EBIT margin decreased by 40 basis points to 22.9% of revenue, mainly driven by the decline in gross margin [4] - Adjusted net income from continuing operations was $249.4 million, with earnings per diluted share increasing by 9% to $2.53 [5] - Free cash flow for the first nine months of fiscal 2026 was $736.6 million, showing year-over-year improvement [6] Business Line Data and Key Metrics Changes - Healthcare segment saw constant currency organic revenue growth of 8%, with service growing 11% and consumables growing 8% [7] - Healthcare capital equipment revenue increased by 7%, with backlog remaining over $400 million [7] - AST segment's constant currency organic revenue grew 8%, with services up 9% and capital equipment revenue up 103% [8] - Life sciences segment experienced a 5% increase in constant currency organic revenue, driven by 11% growth in consumables [8] Market Data and Key Metrics Changes - Orders in the healthcare segment were down 1% year-to-date against tough comparisons from the previous year [7] - The backlog in life sciences is showing strong growth, attributed to recovery in the pharma sector [16] Company Strategy and Development Direction - The company is maintaining its outlook for fiscal 2026, expecting 8%-9% as-reported revenue growth and constant currency organic revenue growth of 7%-8% [9] - The company is focused on mitigating tariff impacts through various strategies, including supplier negotiations and cost reductions [24] - There is a commitment to a more integrated commercial approach in the EMEA region, with structural changes being made to enhance market presence [34] Management's Comments on Operating Environment and Future Outlook - Management expressed caution regarding the fourth quarter, anticipating a slowdown compared to the previous year [12] - The macro environment appears positive, with no significant downside expected for fiscal 2027 [50] - The company is optimistic about its ability to absorb tariff-related costs moving forward [24] Other Important Information - Capital expenditures for the first nine months of fiscal 2026 totaled $278.8 million, with depreciation and amortization at $363.1 million [6] - The company ended the quarter with $1.9 billion in total debt, with a gross debt to EBITDA ratio of approximately 1.2 times [6] Q&A Session Summary Question: Insights on fourth quarter constant currency growth - Management noted a potential slowdown in the second half, maintaining a cautious outlook for the fourth quarter [12][14] Question: Capital equipment backlog activity - Management indicated stability in healthcare backlog and strong growth in life sciences backlog due to recovery in pharma spending [16] Question: Update on tariff mitigation efforts - Management discussed various mitigation strategies, including shifting product movement and supplier negotiations [24] Question: Impact of regulatory proposals on supply chain - Management stated that the ASC shift is generally positive, creating new capacity demands [31] Question: Future acquisition outlook - Management confirmed ongoing interest in smaller acquisitions but emphasized a disciplined approach to larger transformative deals [44] Question: Cash flow guidance and fluctuations - Management expressed confidence in cash flow guidance but noted potential timing issues in the fourth quarter [48] Question: AST Services growth and market conditions - Management acknowledged a weak start to the quarter but noted improvement by December [57]

Core Insights - Align Technology, Inc. (ALGN) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $3.29, a 34.8% increase year over year, exceeding the Zacks Consensus Estimate by 10.1% [1] - Full-year adjusted EPS reached $10.51, reflecting a 12.6% increase from 2024, also surpassing estimates by 2.8% [1] - Total revenues for Q4 were $1.05 billion, up 5.3% year over year, beating the Zacks Consensus Estimate by 1.33% [1] Revenue Performance - Full-year revenues totaled $4.03 billion, a 0.9% increase from 2024, exceeding the Zacks Consensus Estimate by 0.2% [2] - Clear Aligner segment revenues rose 5.5% year over year to $838.1 million, supported by a record volume of 676.9 thousand cases, which was 7.7% higher than the previous year [3] - Imaging Systems & CAD/CAM Services revenues increased 4.2% to $209.4 million, driven by higher volumes and the adoption of the iTero lumina scanner [4] Margin Analysis - Gross profit for Q4 was $683.6 million, down 1.9% year over year, with gross margin contracting 477 basis points to 65.3% due to a 22% increase in the cost of net revenues [5] - Operating income totaled $158.9 million, down 10.3% year over year, with operating margin contracting 263 basis points to 15.2% [5] Financial Position - At the end of Q4, cash and cash equivalents stood at $1.09 billion, up from $1.04 billion at the end of 2024 [6] - Cumulative net cash provided by operating activities was $593.2 million, compared to $738.2 million at the end of 2024 [6] Stock Activity - During the reported quarter, the company repurchased approximately 0.7 million shares at an average price of $142.87 per share, with $831.2 million remaining for future repurchases under the $1.0 billion program [8] Future Outlook - For 2026, Align Technology expects worldwide revenue growth of 3%-4% year over year, with Clear Aligner volume growth projected in the mid-single digits [9] - The Zacks Consensus Estimate for 2026 revenues is $4.18 billion, suggesting a 3.8% growth year over year [9] - For Q1 2026, the company anticipates revenues between $1.010 billion and $1.030 billion, reflecting a 3%-5% year-over-year increase [10] Product Developments - The company launched the Invisalign System with mandibular advancement in the Philippines and Thailand, aimed at correcting Class II skeletal and dental issues [12] - Continued piloting of Exocad ART in several European markets is planned for broader rollout this year [12]

Financial Data and Key Metrics Changes - Third quarter revenue was $339 million, bringing year-to-date revenue to $988 million, with reported revenue reflecting a $153 million impact from last year's portfolio transitions [5][6] - Adjusted earnings per share increased 10% in the quarter to $1.31 and 11% year-to-date to $3.67, indicating strong earnings quality and durability [6][16] - Adjusted gross margin was 60.2% in the third quarter, up 250 basis points year-over-year, and 60.5% year-to-date, up 390 basis points [13][14] - Free cash flow for the third quarter was $74 million, bringing year-to-date free cash flow to $165 million, representing a more than threefold increase compared to the prior year [17][18] Business Line Data and Key Metrics Changes - Hospital revenue was $144 million in the third quarter, down 1% but up 2% year-to-date organically, with strong performance in Blood Management Technologies offsetting softness in Interventional Technologies [6][9] - Blood Management Technologies grew 8% in the quarter and 11% year-to-date, driven by strong sales of TEG 6s disposables and the heparinase neutralization cartridge [6][7] - Interventional Technology revenue declined 12% in the quarter and 8% year-to-date, primarily due to softness in esophageal cooling and OEM-related headwinds [8][9] - Plasma revenue was $139 million, up 3% on a reported basis, with organic growth of 20% in the quarter and 22% year-to-date, driven by share gains and collection volume [9][10] Market Data and Key Metrics Changes - U.S. plasma collections grew in the low double digits in the third quarter, with the company holding approximately 50% global market share [10] - Blood Center revenue was $57 million in the quarter, growing 3% in the quarter and 4% year-to-date organically, driven by international plasma demand [10][11] Company Strategy and Development Direction - The company is focused on returning the Interventional Technologies franchise to sustainable growth in fiscal 2027, with targeted actions underway to strengthen execution [20][21] - The acquisition of Vivasure is expected to enhance the company's leadership in vascular closure, with a $300 million addressable market identified [43][46] - Capital allocation priorities include investing in organic growth, meeting debt obligations, and opportunistically returning cash to shareholders while maintaining balance sheet flexibility [22][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the plasma business, highlighting strong share gains and favorable market conditions [25][27] - The company anticipates continued margin expansion, although future increments may be smaller than those seen in fiscal 2026 [30][31] - Management remains optimistic about the growth potential in the vascular closure market, particularly with the anticipated MVP XL label expansion [38][59] Other Important Information - The company raised its full-year revenue guidance to a decline of 1%-3%, reflecting improved performance across Plasma, Blood Center, and Blood Management Technologies [11] - Adjusted operating income increased 4% year-to-date to $254 million, with adjusted operating margin expanding 200 basis points to 25.7% [15] Q&A Session Summary Question: Insights on plasma growth and sustainability - Management highlighted strong share gains and collection volume growth, indicating a favorable outlook for plasma in fiscal 2027 [25][27] Question: Margin expectations and challenges in the hospital business - Management acknowledged a sequential decline in adjusted operating margin but expressed confidence in overall margin expansion moving forward [30][31] Question: Updates on the IVT business and competition - Management noted that a significant portion of the decline in IVT was due to specific market dynamics, but they are confident in their strategy to return to growth [36][38] Question: Details on the Vivasure acquisition and market positioning - Management emphasized the strategic importance of Vivasure in enhancing their vascular closure portfolio and outlined a measured approach to its market launch [43][46] Question: Sustainability of blood center growth - Management indicated that while the blood center business has shown positive growth, it is subject to order timing and market conditions [79]

Financial Data and Key Metrics Changes - Third quarter revenue was $339 million, bringing year-to-date revenue to $988 million, with reported revenue reflecting a $153 million impact from last year's portfolio transitions [5][6] - Adjusted earnings per share increased 10% in the quarter to $1.31 and 11% year-to-date to $3.67, indicating strong earnings quality and durability [6][16] - Adjusted gross margin was 60.2% in the third quarter, up 250 basis points year-over-year, and 60.5% year-to-date, up 390 basis points [13][14] - Free cash flow for the third quarter was $74 million, bringing year-to-date free cash flow to $165 million, representing a more than threefold increase compared to the prior year [18][19] Business Line Data and Key Metrics Changes - Hospital revenue was $144 million in the third quarter, down 1% but up 2% year-to-date organically, with blood management technologies growing 8% in the quarter [6][9] - Plasma revenue was $139 million, up 3% on a reported basis, with organic growth excluding CSL at 20% in the quarter [9][10] - Blood Center revenue was $57 million in the quarter, growing 3% and 4% year-to-date organically, driven by international plasma demand [10][11] Market Data and Key Metrics Changes - U.S. plasma collections grew in the low double digits in the third quarter, with the company holding approximately 50% global market share [10] - The vascular closure market is experiencing headwinds from increasing PFA adoption, which is affecting growth rates in the electrophysiology market [58][60] Company Strategy and Development Direction - The company is focused on returning the interventional technologies franchise to sustainable growth in fiscal 2027, with targeted actions underway to strengthen execution [20][21] - The acquisition of Vivisure is expected to enhance the company's position in vascular closure, with a market potential of approximately $300 million [44][48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the plasma business, citing strong share gains and favorable market conditions [25][27] - The company anticipates continued margin expansion, although future increments may be smaller than those seen in fiscal 2026 [30][32] Other Important Information - The company raised its full-year revenue guidance, expecting a decline of 1%-3% from a previous range of 1%-4% [11] - Cash on hand at the end of the third quarter was $363 million, up 18% since the start of the fiscal year [19] Q&A Session Summary Question: Insights on plasma growth and sustainability - Management highlighted strong share gains and collection volume growth, indicating a favorable outlook for plasma in fiscal 2027 [25][27] Question: Margin outlook and hospital business challenges - Management acknowledged a sequential decline in adjusted operating margin but expressed optimism about stabilization in the hospital business [28][30] Question: IVT business recovery and competition - Management noted that a significant portion of the decline in IVT was due to specific product disruptions, but they are confident in returning to growth [36][38] Question: Vivisure acquisition details - Management emphasized the strategic importance of Vivisure and its potential to enhance the vascular closure portfolio [44][48] Question: Capital deployment strategy - Management outlined a disciplined approach to capital deployment, prioritizing organic growth and debt reduction while maintaining flexibility for future investments [47][48]

Vivos adds more cutting-edge products to its roster serving the breathing and sleep wellness market LITTLETON, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders, and SoundHealth, a Silicon Valley based health technology company focused on AI enabled, clinically proven allergy and sleep therapeutics, today announced a collaboration ...

Vivos adds more cutting-edge products to its roster serving the breathing and sleep wellness market LITTLETON, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders, and SoundHealth, a Silicon Valley based health technology company focused on AI enabled, clinically proven allergy and sleep therapeutics, today announced a collaboration ...

Core Insights - Nexalin Technology, Inc. has launched its AI-designed virtual clinic platform, NeuroCare®, in collaboration with UC San Diego, aimed at enhancing patient access and reducing costs in brain health care [1][5] - The NeuroCare platform will facilitate remote treatment for conditions such as Alzheimer's, mood disorders, and military-related conditions, utilizing the Gen-3 HALO™ headset for neurostimulation [2][4] Group 1: Product and Technology - The NeuroCare platform integrates with Nexalin's Gen-3 HALO™ headset, providing a comprehensive ecosystem for remote monitoring and treatment of brain health issues [4] - The Gen-3 HALO™ headset is designed to deliver improved Deep Intracranial Frequency Stimulation (DIFS™) in a home setting, enhancing patient experience and treatment outcomes [4][6] Group 2: Business Model and Market Strategy - Nexalin's business model is subscription-based, promoting sustainable revenue and long-term patient engagement through remote monitoring and care continuity [2][3] - The company aims to scale its operations beyond device sales, focusing on data-driven revenue growth and long-term patient retention in global markets [4][5] Group 3: Clinical Research and Collaboration - The launch of the NeuroCare platform coincides with ongoing clinical trials at UC San Diego, where patient enrollment has begun for evaluating Nexalin's non-invasive treatment methods [1][4] - This collaboration is expected to enhance the clinical infrastructure and support the deployment of Nexalin's digital health ecosystem [1][4]

Core Viewpoint - Nexalin Technology, Inc. has launched a new AI-designed virtual clinic platform, NeuroCare®, in partnership with UC San Diego, aimed at enhancing access to neurotherapy for brain health disorders while reducing costs and stigma associated with treatment [1][5] Group 1: Product and Technology - The NeuroCare platform allows patients with conditions such as Alzheimer's, mood disorders, and military-related issues to use Nexalin's HALO headset for neurostimulation treatment at home [2][4] - The Gen-3 HALO™ headset integrates with the NeuroCare platform, providing a comprehensive ecosystem for remote physician oversight and advanced therapy delivery [4] Group 2: Business Model and Market Strategy - The NeuroCare platform operates on a subscription-based model, promoting sustainable revenue and long-term patient outcomes [2][3] - Nexalin aims to transition from device sales to long-term recurring revenue through data-driven clinical outcomes and patient retention strategies [4][5] Group 3: Clinical Research and Development - The collaboration with UC San Diego builds on ongoing clinical research, with patient enrollment already underway for trials evaluating Nexalin's non-invasive treatment methods [1][4] - The launch of the Gen-3 HALO headset is part of a broader strategy to address the global mental health epidemic through innovative neurostimulation technology [6]